mRNA |
BRD-K13185470 |
CTRPv2 |
pan-cancer |
AAC |
-0.028 |
0.7 |
mRNA |
ML239 |
CTRPv2 |
pan-cancer |
AAC |
0.014 |
0.7 |
mRNA |
Ki8751 |
CTRPv2 |
pan-cancer |
AAC |
0.014 |
0.7 |
mRNA |
BRD9876:MK-1775 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.041 |
0.7 |
mRNA |
BRD-K02251932 |
CTRPv2 |
pan-cancer |
AAC |
0.015 |
0.7 |
mRNA |
BRD-K80183349 |
CTRPv2 |
pan-cancer |
AAC |
0.013 |
0.7 |
mRNA |
thalidomide |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.7 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.013 |
0.7 |
mRNA |
BRD-K17060750 |
CTRPv2 |
pan-cancer |
AAC |
-0.014 |
0.7 |
mRNA |
navitoclax:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.014 |
0.7 |